this is also hypnosis. this is profanity. all is well message flying saucers, why my neighbor from this case cured andrey with hypnosis so i must say the red zaporozhets yes, but only one red zaporozhets in our region is over 7,000. how will we search? where the prosecutor of the republic gave a special instruction to throw all his strength into the search for strangulation. so we will throw all of all of all the police as a threat and the vigilantes will use literally everyone. that's what will happen.

in russia, there is a list of medicines with which, allegedly, interruptions may occur during years, oh, what are we talking about and what is the truth, how does the relevant market behave in general under sanctions, what drugs

are becoming more expensive and why, what do we do no worse than europe or america and what is our achilles heel, let's talk about it with the head of the association of russian pharmaceutical manufacturers viktor dmitriev? recently, people in the country started talking about the fact that about a hundred medicines, including those from the list of the ministry of health, were under the threat of a shortage. this is slandered by evil tongues or there is some truth in this, but certainly. eh, there is some truth and a fairly high share. here uh, such a list we have appeared for the first time. e. in general, i treat him in two ways on the one hand. i suspect that this list will add degrees of anxiety to the public on the other side. we perceive it as a certain signal. in this case, we are business and probably the medical community. as an example, the treatment of tuberculosis, because these are the antibiotics that were used there 30 years ago. we gradually

moved away from them, newer ones appeared. and today we understand that those antibiotics today begin to work better, because they have not been used for a long time window extra stability has increased curiously there are such paradoxes. yes, tell me, what are the alternatives to a scarce foreign drug. uh, to offer, uh, to the client, i mean, the population of our producers, not medicines, nor medical products, did not fall under the sanctions and, accordingly, not a single company. uh, foreign countries have not announced that they are leaving our market, so far there has been only one drug that has left - this is saldenafil, the phizer company, well, in other words, viagra well, the first one, first, there are many analogues. secondly, i think we can manage without him. well, yes, that's why here we have, uh, in general, more optimism than pessimism. second. this means that individual specific trade names may disappear or disappear.

it is tied to the so-called international or proprietary name, that is, to the active substance that has a therapeutic effect, we are increasing the production of drugs with these mns within the country, if there are opportunities for this, and in general we are moving away from the term about imported, because what, in principle, we perceive it as our own, because these are the jobs, these taxes that remain here and here , the most important thing is the products and the same companies that i mentioned. today, they probably face the same problems as companies with 100% russian capital. claims of the problem, when the ingredients are delivered here , it is easier to deliver medicines to the country. than to produce it domestically, because ready-made medicines e does not fall under sanctions. but any ingredient, it can be double destination. well, a simple example is the lacquer that we use to process the tube from the inside, when we fill it there with creams or ointments,

this lacquer suddenly turned out to be dual-purpose, it turns out that it is used somewhere else and there are many such examples in the aircraft industry. e, well , unfortunately, the further, the more, that is, we do not know what will be announced. tomorrow we are a dual-use commodity today for you can see the biggest problems with supplies from europe from america that's right, as for the ingredients, as for the packaging, so we are refocusing on southeast asia mainly. uh, let's look at what is in china, what is in pakistan, what is in india, if we used to have guaranteed logistics there with a delivery of 30-35 days, then today, at best, it is 90-95 days and at the same time the planning horizon. there is no guarantee for a week. so you mentioned packaging problems and uh, can you elaborate for the uninitiated. the fact is that, in fact, in the twenty-first year, when mandatory marking was introduced. we were forced to.

this is especially true for returns from low price segment of those drugs that are up to 100 rubles. uh, switch to imported cardboard due to the fact that the markings on our cardboard were blurry like a blot. yeah, and accordingly were forced to buy this cardboard. this made the product more expensive. we are talking about it. well, there are cheap drugs there, which are citramon, it is there from 10 there to 15 rubles. it turned out that the packaging is more expensive than the tablet itself, the second moment is foil. it seems to be russian aluminum, but the price is determined by the london stock exchange, so foil is also becoming more expensive the cost is constantly rising, we, uh, until the new year, we actually kept on old stocks. now we are moving to new stocks. more precisely, what they bought during the year. and all this will be and was more expensive and will be, respectively, more expensive now when

we sell it approximately, it is clear how much percentage was calculated by about 34% on average in the market. this is a solid amount. yes, we understand this very well. e. well, you said that a very serious increase is possible. prices for medicines medicines, i just said the cost, because we are not always allowed to raise prices. and this is also a big problem and often our pharmaceutical manufacturers operate at a loss. you know, those companies that have a large portfolio. as far as the cent is concerned, we have a list of vital and essential medicines already on gdp. prices are fixed for this list. you are here, uh, working, relatively speaking, at a loss, but you compensate for this loss at the expense of other drugs, where prices are not regulated. there you can pick up above, for example, related drugs that are on the same list on the gdp is there,

uh, one percent 2%, but the lists that are outside the already gdp there are eight nine and more depending on the level of inflation. so to put it this way, i was more guided by 4% , four or six, which they said earlier this year, of course, inflation is higher there, therefore , let's see what will happen well, i think that the picture will be a classic percentage. it is approximately the same, you know, there were data , uh, rosstat published that in 2022 we increased the production of pharmaceutical drugs by 8% if i'm not mistaken, but we, uh, how would there be growth opportunities, there are still enough sites for this or some other conditions, when there, how is it official statistics come from ours or growth? i ask, what is the growth, because our market is changing, either in terms of money, or in packages in terms of money. in fact, we see this growth, but just due to the rise in the price of everything, and therefore the growth in packages. how much, by the way, in money? well, about, well,

about today. here is what you said somewhere there is about 8-12%. i do not mean in absolute rubles. what is a million billion? uh, our market. yes, uh, the market was priced in dollars. and the years were somewhere around 18-20 billion. that is, it was larger than the car market. these are, in general, solid sums. the third of these is the budget. that is, this is the money that goes to government purchases for e, hospitals for outpatient clinics and programs. there, relatively speaking, oncology tuberculosis. this is solid money. is there. uh, evaluation would like evaluation in packages. here it is in the packages. we already we haven't seen growth in a long time. uh-huh, that is, this growth in money. well, uh, i don't know what it gives to the patient, it's actually more like an economic unit. although we understand that cheaper drugs often go away with more expensive ones, but we hope that they are more effective.

although you know, here, there are some old preparations that are already there. well, i don't want to say 100 years, but decades on the market. uh, they are economically few, maybe, uh, and profitable, but they are used to. and what happens in our uniform with the equipment and is there such a task? this is what is called 100% replacement with equipment, and we probably have the biggest problem, because we are 100% dependent on foreign supplies. today , china actually produces good equipment. they have risen great and it is natural that today we are primarily looking at them, because european companies are more difficult with europe, but in particular the german ones are ready to put the line in full, validate it and launch it, they take care of all the problems with logistics, but you can't buy this line piece by piece because again every piece is a

dual purpose piece. uh, service issues also appeared. hmm, we are trying to solve them. something it is possible to replace some spare parts , some are also difficult to replace, because we simply do not have such machines. here, uh, with regard to pharmaceutical thought, let's say. so what we do best. what drugs and in general, in principle, on our market , what is the share of what is called domestic developments, as for thought, i always said that we were there to shoe a flea. we can today have such a paradigm in order for a new drug to appear, a new molecule in principle. well, not that they changed the shell there, they improved it. uh, for this you need to understand that you will return the investment that you invest. uh, in the study into the development of this drug. we don’t have such guarantees today, so it happens like this, but first some

absolutely new imported drug comes in, which is under patent protection. and after that, this drug gets into the lists and into the standards treatment. well, as a simple example of spirase. this is from the spinal muscular reflex in children. this is a very expensive drug. there, the price in rubles is millions, there are more than 50 million, in my opinion, there are no more. so, accordingly, none of our companies took on the development until we saw that it began to be funded, as soon as it began to be funded. we have proposals for the production of analogues of spinase, but so far we are doomed to create some kind of analogues. yes i correctly i understand, well partly. yes, although we, for example, have enterprises, a generium. this is the only one in the world. an enterprise that produces all blood factors is more of such an enterprise in the world. no, the market, it seems that we have a decent 18 billion dollars to say, for example, uh, that is, this promising direction needs to be developed.

look, then, out of these 18. i said that only half. well, it is not half, somewhere around a third of the budget, and yet we are guided precisely by the budget, because modern drugs. they are very expensive. it's connected with cost and with a very long development, that is. it takes me generally from 7 to 10 years 7 10. yes, it’s impossible to speed it up, because a lot of time is given to the clinic and the clinic, so to speak. and now, if a mouse is supposed to give birth there in 90 days, then this process cannot be accelerated, because otherwise the evidence base will already be completely different, when good results appear at the first stage, then a large company buys, uh, either the entire company, or there the products are already further brought home. well , i can say that we have done the first uh, anticoagulant in russia such anticoagulants. no, in principle, only foreign ones. uh, last year the country

spent 24 billion on the purchase of foreign anticoagulants. but now we have registered it and i hope that trace will appear on the market, what about the personnel? our industry trains technologists. uh, how would they prepare chemical universities that belong to the system of the ministry of education of pharmacists prepare medical universities that belong to the system of the ministry of health and, accordingly, people for enterprises for the pharmaceutical industry. eh, it turns out to find it right away prepared is very difficult, because either this technology, which does not know pharma, or it is pharmacists who do not know the technology well, they want to teach there, so to speak. this is why we are constantly talking about the need for some kind of unified , nevertheless, to make a qualified training program. well, at least there, the remaining courses. eh, basically, enough of the guys goes. here we are holding

pharmaceutical olympiads and in general, uh, we started it as some kind of pr, and then we realized that this is also a forge of personnel in the truest sense of this words, because in the best guys. immediately the company was taken away. they gave them apartments to rent if they needed to change their place of residence, because we collected from all over the country. but nevertheless, there is a shortage, for example, of good technologists, it exists, e, it also exists in the salary plan , because if we have a food service across the road, there is a brewery, or, uh, oil refining, then yes, and accordingly, people some starter salaries. e. well, we can talk about regions. that is, we maintain the average salary of a child everywhere. well, a good tech. today it starts. she probably, well, i mean, the main technology is from 250-300, there is a higher salary.